AIM: To investigate the characteristics of the progression of islet beta cell function in Chinese latent autoimmune diabetes in adult (LADA) patients with glutamic acid decarboxylase antibody (GAD-Ab) positivity, and to explore the prognostic factors for beta cell function. METHODS: Forty-five LADA patients with GAD-Ab positivity screened from phenotypic type 2 diabetic (T2DM) patients and 45 T2DM patients without GAD-Ab matched as controls were followed-up every 6 mo. Sixteen patients in LADA1 and T2DM1 groups respectively have been followed-up for 6 years, while 29 patients in LADA2 and T2DM2 groups respectively for only 1.5 years. GAD-Ab was determined by radioligand assay, and C-peptides (CP) by radioimmune assay. RESULTS: The percentage of patients whose fasting CP (FCP) decreased more than 50% compared with the baseline reached to 25.0% at 1.5(th) year in LADA1 group, and FCP level decreased (395.8+/-71.5 vs 572.8+/-72.3 pmol/L, P<0.05) at 2.5(th) year and continuously went down to the end of follow-up. No significant changes of the above parameters were found in T2DM1 group. The average decreased percentages of FCP per year in LADA and T2DM patients were 15.8% (4.0-91.0%) and 5.2% (-3.5 to 35.5%, P=0.000) respectively. The index of GAD-Ab was negatively correlated with the FCP in LADA patients (r(s)=-0.483, P=0.000). The decreased percentage of FCP per year in LADA patients were correlated with GAD-Ab index, body mass index (BMI) and age at onset (r(s)=0.408, -0.301 and -0.523 respectively, P<0.05). Moreover, GAD-Ab was the only risk factor for predicting beta cell failure in LADA patients (B=1.455, EXP (B)=4.283, P=0.023). CONCLUSION: The decreasing rate of islet beta cell function in LADA, being highly heterogeneous, is three times that of T2DM patients. The titer of GAD-Ab is an important predictor for the progression of islet beta cell function, and age at onset and BMI could also act as the predictors.
AIM: To investigate the characteristics of the progression of islet beta cell function in Chinese latent autoimmune diabetes in adult (LADA) patients with glutamic acid decarboxylase antibody (GAD-Ab) positivity, and to explore the prognostic factors for beta cell function. METHODS: Forty-five LADA patients with GAD-Ab positivity screened from phenotypic type 2 diabetic (T2DM) patients and 45 T2DM patients without GAD-Ab matched as controls were followed-up every 6 mo. Sixteen patients in LADA1 and T2DM1 groups respectively have been followed-up for 6 years, while 29 patients in LADA2 and T2DM2 groups respectively for only 1.5 years. GAD-Ab was determined by radioligand assay, and C-peptides (CP) by radioimmune assay. RESULTS: The percentage of patients whose fasting CP (FCP) decreased more than 50% compared with the baseline reached to 25.0% at 1.5(th) year in LADA1 group, and FCP level decreased (395.8+/-71.5 vs 572.8+/-72.3 pmol/L, P<0.05) at 2.5(th) year and continuously went down to the end of follow-up. No significant changes of the above parameters were found in T2DM1 group. The average decreased percentages of FCP per year in LADA and T2DM patients were 15.8% (4.0-91.0%) and 5.2% (-3.5 to 35.5%, P=0.000) respectively. The index of GAD-Ab was negatively correlated with the FCP in LADA patients (r(s)=-0.483, P=0.000). The decreased percentage of FCP per year in LADA patients were correlated with GAD-Ab index, body mass index (BMI) and age at onset (r(s)=0.408, -0.301 and -0.523 respectively, P<0.05). Moreover, GAD-Ab was the only risk factor for predicting beta cell failure in LADA patients (B=1.455, EXP (B)=4.283, P=0.023). CONCLUSION: The decreasing rate of islet beta cell function in LADA, being highly heterogeneous, is three times that of T2DM patients. The titer of GAD-Ab is an important predictor for the progression of islet beta cell function, and age at onset and BMI could also act as the predictors.
Authors: K Decochez; B Keymeulen; G Somers; H Dorchy; I H De Leeuw; C Mathieu; R Rottiers; F Winnock; K ver Elst; I Weets; L Kaufman; D G Pipeleers; F K Gorus Journal: Diabetes Care Date: 2000-08 Impact factor: 19.112
Authors: A Falorni; G Gambelunghe; F Forini; G Kassi; A Cosentino; P Candeloro; G B Bolli; P Brunetti; F Calcinaro Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: B Littorin; G Sundkvist; W Hagopian; M Landin-Olsson; A Lernmark; J Ostman; H J Arnqvist; G Blohmé; J Bolinder; J W Eriksson; F Lithner; B Scherstén; L Wibell Journal: Diabetes Care Date: 1999-03 Impact factor: 19.112
Authors: R Turner; I Stratton; V Horton; S Manley; P Zimmet; I R Mackay; M Shattock; G F Bottazzo; R Holman Journal: Lancet Date: 1997-11-01 Impact factor: 79.321
Authors: Frederick C Goetz; Joseph Roel; David R Jacobs; Jose Barbosa; Peter Hannan; Jerry Palmer; William Hagopian Journal: Metabolism Date: 2002-02 Impact factor: 8.694
Authors: R Bonfanti; E Bazzigaluppi; G Calori; M C Riva; M Viscardi; E Bognetti; F Meschi; E Bosi; G Chiumello; E Bonifacio Journal: Diabet Med Date: 1998-10 Impact factor: 4.359
Authors: S V Hope; A G Jones; E Goodchild; M Shepherd; R E J Besser; B Shields; T McDonald; B A Knight; A Hattersley Journal: Diabet Med Date: 2013-06-12 Impact factor: 4.359